Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID).

Drott K, Hagberg H, Papworth K, Relander T, Jerkeman M.

Blood Adv. 2018 Jun 26;2(12):1386-1392. doi: 10.1182/bloodadvances.2018019240.

2.

The transcriptional coregulator NAB2 is a target gene for the Wilms' tumor gene 1 protein (WT1) in leukemic cells.

Nilsson HJ, Montano G, Ullmark T, Lennartsson A, Drott K, Järvstråt L, Nilsson B, Vidovic K, Gullberg U.

Oncotarget. 2017 Aug 3;8(50):87136-87150. doi: 10.18632/oncotarget.19896. eCollection 2017 Oct 20.

3.

The HDAC inhibitor valproate induces a bivalent status of the CD20 promoter in CLL patients suggesting distinct epigenetic regulation of CD20 expression in CLL in vivo.

Scialdone A, Hasni MS, Damm JK, Lennartsson A, Gullberg U, Drott K.

Oncotarget. 2017 Jun 6;8(23):37409-37422. doi: 10.18632/oncotarget.16964.

4.

Anti-apoptotic quinolinate phosphoribosyltransferase (QPRT) is a target gene of Wilms' tumor gene 1 (WT1) protein in leukemic cells.

Ullmark T, Montano G, Järvstråt L, Jernmark Nilsson H, Håkansson E, Drott K, Nilsson B, Vidovic K, Gullberg U.

Biochem Biophys Res Commun. 2017 Jan 22;482(4):802-807. doi: 10.1016/j.bbrc.2016.11.114. Epub 2016 Nov 23.

PMID:
27889611
5.

Distinct global binding patterns of the Wilms tumor gene 1 (WT1) -KTS and +KTS isoforms in leukemic cells.

Ullmark T, Järvstråt L, Sandén C, Montano G, Jernmark-Nilsson H, Lilljebjörn H, Lennartsson A, Fioretos T, Drott K, Vidovic K, Nilsson B, Gullberg U.

Haematologica. 2017 Feb;102(2):336-345. doi: 10.3324/haematol.2016.149815. Epub 2016 Sep 9.

6.

The hematopoietic tumor suppressor interferon regulatory factor 8 (IRF8) is upregulated by the antimetabolite cytarabine in leukemic cells involving the zinc finger protein ZNF224, acting as a cofactor of the Wilms' tumor gene 1 (WT1) protein.

Montano G, Ullmark T, Jernmark-Nilsson H, Sodaro G, Drott K, Costanzo P, Vidovic K, Gullberg U.

Leuk Res. 2016 Jan;40:60-7. doi: 10.1016/j.leukres.2015.10.014. Epub 2015 Nov 2.

PMID:
26563595
7.

Pharmacologically relevant doses of valproate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo.

Damm JK, Gordon S, Ehinger M, Jerkeman M, Gullberg U, Hultquist A, Drott K.

Exp Hematol Oncol. 2015 Jan 26;4:4. doi: 10.1186/2162-3619-4-4. eCollection 2015.

8.

The histone deacetylase inhibitor valproic acid sensitizes diffuse large B-cell lymphoma cell lines to CHOP-induced cell death.

Ageberg M, Rydström K, Relander T, Drott K.

Am J Transl Res. 2013;5(2):170-83. Epub 2013 Mar 28.

9.

The p53 target gene TRIM22 directly or indirectly interacts with the translation initiation factor eIF4E and inhibits the binding of eIF4E to eIF4G.

Petersson J, Ageberg M, Sandén C, Olofsson T, Gullberg U, Drott K.

Biol Cell. 2012 Aug;104(8):462-75. doi: 10.1111/boc.201100099. Epub 2012 May 31.

PMID:
22509910
10.

Inhibition of geranylgeranylation mediates sensitivity to CHOP-induced cell death of DLBCL cell lines.

Ageberg M, Rydström K, Lindén O, Linderoth J, Jerkeman M, Drott K.

Exp Cell Res. 2011 May 1;317(8):1179-91. doi: 10.1016/j.yexcr.2011.02.006. Epub 2011 Feb 13.

PMID:
21324313
11.

The human IFN-inducible p53 target gene TRIM22 colocalizes with the centrosome independently of cell cycle phase.

Petersson J, Lönnbro P, Herr AM, Mörgelin M, Gullberg U, Drott K.

Exp Cell Res. 2010 Feb 15;316(4):568-79. doi: 10.1016/j.yexcr.2009.12.007. Epub 2009 Dec 16.

PMID:
20006605
12.

Identification of a novel and myeloid specific role of the leukemia-associated fusion protein DEK-NUP214 leading to increased protein synthesis.

Ageberg M, Drott K, Olofsson T, Gullberg U, Lindmark A.

Genes Chromosomes Cancer. 2008 Apr;47(4):276-87. doi: 10.1002/gcc.20531.

PMID:
18181180
13.

Regulation of the interferon-inducible p53 target gene TRIM22 (Staf50) in human T lymphocyte activation.

Obad S, Olofsson T, Mechti N, Gullberg U, Drott K.

J Interferon Cytokine Res. 2007 Oct;27(10):857-64.

PMID:
17970695
14.

Expression of the IFN-inducible p53-target gene TRIM22 is down-regulated during erythroid differentiation of human bone marrow.

Obad S, Olofsson T, Mechti N, Gullberg U, Drott K.

Leuk Res. 2007 Jul;31(7):995-1001. Epub 2007 Jan 24.

PMID:
17257675
15.

Staf50 is a novel p53 target gene conferring reduced clonogenic growth of leukemic U-937 cells.

Obad S, Brunnström H, Vallon-Christersson J, Borg A, Drott K, Gullberg U.

Oncogene. 2004 May 20;23(23):4050-9.

PMID:
15064739

Supplemental Content

Support Center